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ABSTRACT
The extent of genetic and epigenetic diversity between and within
patient tumors is being mapped in ever more detail. It is clear that
cancer is an evolutionary process in which tumor cell intrinsic and
extrinsic forces shape clonal selection. The pre-clinical oncology
pipeline uses model systems of human cancer – including mouse
models, cell lines, patient-derived organoids and patient-derived
xenografts – to study tumor biology and assess the efficacy of
putative therapeutic agents. Model systems cannot completely
replicate the environment of human tumors and, even within the
same cancermodel, data are often irreproducible between laboratories.
One hypothesis is that ongoing evolutionary processes remain relevant
in laboratorymodels, leading to divergenceover time. In a recent edition
of Nature, Ben-David and colleagues showed that different stocks of
widely used cancer cell lines – a staple of cancer research over many
decades – are highly heterogeneous in terms of their genetics,
transcriptomics and responses to therapies. The authors find
compelling evidence of positive selection based on ongoing
mutational processes and chromosomal instability. Thus, the origin,
culture conditions and cumulative number of population doublings of
cell lines likely influence experimental outcomes. Here, we summarize
the key findings of this important study and discuss the practical
implicationsof thiswork for researchers using cell lines in the laboratory.
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To study human cancer biology, researchers can use patient biopsies
or tissue from the surgical resection of tumors. However, this tissue
represents a single snapshot in the life history of that tumor,
typically at an advanced stage. In order to investigate the dynamic
genetic and epigenetic course of cancer initiation, progression and
metastasis, experimental model systems are required. More recent
systems include genetically engineered mouse models (GEMMs)
(Day et al., 2015), patient-derived xenografts (PDXs) (Byrne et al.,
2017) and patient stem cell-derived organoids (Drost and Clevers,
2018), but by far the most commonly used remain cancer cell lines
(van Staveren et al., 2009).
Cancer models are typically appraised in terms of how
completely they recapitulate the features of the cancer of interest.
Of course, none do so perfectly. GEMMs, for example, allow the
monitoring of tumorigenesis in a longitudinal manner in vivo, but
are limited by species differences in oncogenic pathogenesis, the
shorter lifespan of mice and, often, by the artificial, simultaneous
introduction of multiple oncogenic driver events. Cell lines have the
advantage of being derived from patients and are more easily
manipulated in the laboratory. Nevertheless, the cancer research
community has long appreciated that cell lines do not completely
recapitulate human disease (Hughes et al., 2007), as only a subset of
patient tumors, and tumor cells, are amenable to growth on plastic
tissue culture substrates. The establishment of pure, proliferative
cultures of malignant cells leads to selection as the differentiated
features of tumors are frequently lost, and we readily acknowledge
that ‘substrains’ of cell lines exist, likely due to clonal evolution
during long-term culture. Now, in experiments published in Nature
(Ben-David et al., 2018), Uri Ben-David and colleagues have revealed
the extent to which individual cancer cell lines are heterogeneous and
continue to diversify during long-term cell culture (Fig. 1).
Initially, the authors tested the hypothesis of clonal variation
within established cell lines by re-analyzing published whole-
exome sequencing data, originating from the Broad and the Sanger
Institutes’ cancer cell line sequencing efforts, applying the same
methodology to both data sets. Between the two sources of cell line
data, a median of 19% of the detected non-silent mutations and 26%
of gene copy number alterations (CNAs) were present in one data set
but not the other. This discordance prompted the authors to examine
the genetic variability within the cell lines in detail.
Laboratories around the world maintain different substrains of cell
lines, so the authors sourced 27 independent vials of MCF7, an
estrogen receptor-positive breast cancer cell line, predominantly
from two major Broad Institute projects [Cancer Cell Line
Encyclopedia (https://portals.broadinstitute.org/ccle) and Connectivity
Map (https://clue.io/cmap)]. The MCF7 strains also demonstrated
substantial heterogeneity in their mutational status, chromosomal
rearrangements and CNAs. Deep, targeted sequencing of 447 genes
revealed that just 35% of coding non-synonymous single-nucleotide
variants (SNVs) and insertions and deletions were shared by all of
the strains, while 29% were unique to a single substrain. Even when
specific mutations were present in all strains, the allelic fraction,
defined as the number of variant reads divided by the total number
of reads at a specific genomic locus, varied substantially. The
authors highlight an activating PIK3CA mutation (G1633A), for
which the allelic fraction fluctuated between 0.21 and 0.7, as an
example likely to have functional consequences. Differences in
larger genomic rearrangements, such as arm-level copy number
events, and differential copy number gains and/or losses in
hundreds of genes were also evident among strains. Of those
events, only 13% of gains and 21% of losses were present across all
strains, with 7% of gains and 13% of losses being unique to a single
strain. Importantly, these events affected genes such as TP53, EGFR
and PTEN, which are known to be gained or lost during breast
cancer pathogenesis. This indicated that individual existing strains
of the MCF7 cell line might be more biologically relevant to the
study of estrogen receptor-positive breast cancer than others.
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Fig. 1. See next page for legend.
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Reassuringly, the overall genetic distance between substrains
appeared to correlate with how recently the cell lines diverged from
each other. This means that two strains growing in independent
laboratories for 2 years likely have more in common than two strains
that have been evolving in separate laboratories for 10 years.
However, strains can diverge rapidly, as two versions of the cell line
that were only a few passages apart had acquired an additional
mutation in one of the genes included in the analysis. Such
divergence could hinder the reproducibility of experiments and
explain the discrepancies within experimental replicates.
Next, the authors demonstrated that positive selection, rather than
stochastic variation, underlies the genetic heterogeneity of MCF7
strains. Barcoding experiments of five biological replicates grown in
five different culture conditions demonstrated that the same pre-
existing subclones were being selected for in each culture condition.
These data indicate that even minor changes in cell culture protocols
can alter the cell line genotype through selection. Furthermore,
genetic heterogeneity is re-established when culturing single cell-
derived clones over time. This, combined with the observation
that time in culture, rather than freeze-thaw cycles, was the main
contributor to genetic divergence between strains, supports the
authors’ conclusion that ongoing genomic instability, rather than
stochastic bottlenecks imposed by culture routines, underlies the
variation in subclonal composition of MCF7 cells.
Beyond the measured genomic variation, and despite identical
culture conditions, the 27MCF7 strains also exhibited transcriptomic
variation, albeit with an overall similarity in global gene expression
profiles. Clustering by transcriptomic profiles was very similar to
clustering by genomic distance, suggesting that differential pathway
activation due to varied genetic background underlies the gene
expression differences between strains. However, variations in cell
culture substrates, media and culture environments likely mean that
this study, performed in a single laboratory using identical culture
conditions, underestimated the inter-laboratory variability in gene
expression of any given cell line. Using quantitative live-cell
imaging, the authors measured several properties linked to cellular
function. Consistent with anecdotal experiences of working with cell
lines, the authors found that the doubling times and morphology of
the MCF7 cells were widely variable among strains, and also
correlated with the observed genomic and gene expression variation.
Ben-David et al. validated their MCF7 findings in the KRAS-
mutant lung adenocarcinoma cell line A549 (Giard et al., 1973),
which is widely used in lung cancer research. They observed a
similar variability between 23 A549 strains; the key lung
adenocarcinoma driver gene CDKN2A was lost in five of the
strains and KRAS pathway components were highly variable in
transcriptomic analyses. Targeted sequencing results from 11
further cell lines, and similar results from an investigation of the
genomic, transcriptomic and phenotypic heterogeneity of HeLa
cells from 13 independent laboratories (Liu et al., 2018), suggest
that Ben-David et al.’s findings have universal relevance to cell line
culture. Assessing the extent and importance of this variability for
specific cell lines will be a new challenge for the field.
Of particular concern for cell biologists, the observed
heterogeneity was not limited to transformed cells: 15 strains of
MCF10A, a spontaneously immortalized ‘normal’ human
mammary cell line, also demonstrated genomic heterogeneity
levels comparable to those of transformed cell lines. Another
recent study found that primary murine epithelial cells were more
prone to chromosome mis-segregation in 2D cultures than when
grown in 3D organoid culture or in vivo, where tissue architecture
maintains a high chromosome segregation fidelity through the
enhanced correction of kinetochore merotelic attachments (Knouse
et al., 2018). In this sense, the artificial nature of 2D cell culture on
plastic might recapitulate an important aspect of epithelial
carcinogenesis – the lack of epithelial polarity and organized
tissue structure. Some primary cell cultures, such as mouse
embryonic fibroblasts (Berenjeno et al., 2017), display high rates
of chromosomal instability. Clinically, however, the success of
primary epithelial stem cell therapies in patients (Hynds et al., 2018)
– where engrafted cells are karyotypically normal – suggests that
this might not be a universal 2D cell culture phenomenon. Tissue- or
species-specific differences may affect chromosomal stability
profiles in vitro, and optimized 2D culture conditions might
reduce the frequency of mis-segregation events. Moreover, the
observation that unstable, late-stage tumors give rise to more
unstable cell lines (Ben-David et al., 2018), coupled with previous
data showing that tetraploid genomes undergo more rapid copy
number evolution than diploid genomes within the HCT-116 cell
line (Dewhurst et al., 2014), suggests that the intrinsic genomic
(in)stability of the initiating population is relevant to the future
evolution of a cell line.
Cell lines are an important source of information when
investigating potential new therapies, so a crucial question arising
from Ben-David et al.’s initial experiments is whether the genomic
and transcriptomic heterogeneity of cell lines affects our ability to
appraise new therapeutic agents. In a screen of 321 compounds, the
drug response of the different MCF7 strains was highly variable:
among the 55 compounds that inhibited the growth of at least one
strain by more than 50%, 48 of these showed <20% growth
inhibition in at least one other strain. These differences in drug
response are underpinned by genetic and transcriptomic differences
and go some way to explaining the frequent lack of reproducibility
between laboratories. The results also have implications for studies
of drug resistance, as previous studies showed that rare resistant
clones are present within cell lines and emerge to become dominant
under heavy selection, such as with cancer cells harboring activating
mutations in EGFR grown under EGFR inhibition (Hata et al.,
2016). If different subclonal compositions exist in different
laboratories, then conflicting outcomes, even in response to the
same therapy, are likely.
The formal recognition of the heterogeneity propagated by cell
line culture adds to our uncertainty about how to interpret data from
cancer model systems, particularly in light of the recent advances
unveiling the extent of intratumoral heterogeneity detected in
patient tumors. The problems with cell culture systems highlighted
by Ben-David et al. strongly support efforts to systematically
develop new patient-derived cancer models to reduce our reliance
on poorly defined cell lines that were established before the
emergence of next generation sequencing and have been subjected
to extensive ongoing selection. These new ‘close-to-patient’models
likely reflect the patient’s disease more accurately (Hidalgo et al.,
Fig. 1. Genomic diversity in cell line cultures. Cell lines are proliferative
cultures of transformed tumor cells derived from patient samples and grown on
2D tissue culture substrates. Selection occurs at multiple levels during cell line
derivation: non-cancer cells are excluded and proliferative cells are selected
for, leading to a bias for poorly differentiated cells. Ben-David and colleagues
provide evidence that cell lines are genomically unstable during propagation
with ongoing selection based on environmental factors, such as cell culture
media types (Ben-David et al., 2018). This genomic heterogeneity, which
arises through both mutational and chromosomal instability processes, alters
the transcriptional profile and drug response of cell lines, and might explain
how using the same cell lines in different studies can lead to contradictory
results.
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2014; Weeber et al., 2015), even though they are probably subject to
the same evolutionary pressures as conventional cancer cell lines
during propagation. Although PDX models are broadly thought to
preserve the genotype of the tumor from which they are derived
(Hidalgo et al., 2014), there is some evidence that, similar to
metastases in patients, they might arise from a subclone of the
primary tumor (Ding et al., 2010). Characterizing greater numbers of
patients in detail will clarify this issue and shed light on the possible
differences in selection pressures between subcutaneous and
orthotopic PDX models (Stewart et al., 2017). Ben-David et al.
have previously demonstrated that ongoing, ex vivo evolution is
relevant in PDX models, where CNAs that were not found in the
original tumor emerged after serial passaging (Ben-David et al.,
2017). Detailed and repeated characterization of new cell and
organoid lines is also important for reproducibility, as contamination
and overgrowth of cancer cell cultures with tumor-associated
fibroblasts or normal epithelial cells occurs frequently (Gao et al.,
2017; Sachs et al., 2018).
We believe that these data signal an end to the era in which
researchers informally acknowledge that different strains of cancer
cell lines are heterogeneous and unstable over long-term passage,
but in practice treat them as though they were clonal entities. There
are already established measures to minimize irreproducibility
between laboratories, such as cell line identification (Fusenig et al.,
2017), mycoplasma testing (Lorsch et al., 2014), the use of carefully
validated reagents (Shah et al., 2018) and robust statistical standards
(Loken and Gelman, 2017; Weissgerber et al., 2017). In addition to
these, researchers can take several practical steps to mitigate and,
perhaps, also utilize the heterogeneity of cell line strains. When best
practice guidelines (Geraghty et al., 2014) are re-written, they might
now recommend the following:
(1) For existing cell lines, each laboratory’s strain should be
profiled. Reference genomes for cell lines [e.g. the Broad
Institute’s Cancer Cell Line Encyclopedia (https://portals.
broadinstitute.org/ccle) or the Sanger Institute’s Cell Lines
Project (https://cancer.sanger.ac.uk/cell_lines)] should be
used for broad direction but specific mutation/pathway
status should be confirmed locally.
(2) On adoption of new cell lines, identical cryovials of very
early passage cell lines should be established on arrival and
later passage working stocks derived from just one of these.
Master stocks could then be used for validation of key
findings prior to publication.
(3) More rigorous monitoring and reporting of population
doublings should become the norm, and substitute the
current ‘passage number’ convention, which is imprecise.
Cell lines should preferably be used within a defined
window to minimize genetic drift.
(4) The optimization, agreement and implementation of
international ‘standard’ culture conditions for individual
cell lines together with the documentation of heterogeneity
metrics (e.g. measures of genomic divergence per passage
in those conditions) in datasheets.
(5) The reassessment of genomic landscape after significant
culture bottlenecks induced by selection and/or single cell
cloning (e.g. in CRISPR-Cas9 gene editing experiments).
In summary, Ben-David et al. reveal the scale of heterogeneity
between strains of cancer cell lines and the ongoing nature of the
processes that underlie this heterogeneity. Importantly, these
processes are unlikely to be similar to the ongoing genomic
processes in human tumors, and mean that as cell lines – already
an idiosyncratic representation of a single patient’s cancer – are
expanded long-term, they become even less representative of human
disease. Importantly, recognizing the variability within laboratory
cancer models, whether in vitro or in vivo, presents opportunities for
researchers to improve the reporting and reproducibility of pre-
clinical cancer research.
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